Tag: Carcinoid Cancer Foundation
RadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients
Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund. According to Ebrahim…
READ MORE
Carcinoid Cancer Foundation Symposium Features Leading NET Cancer Specialists & a Patient Panel
What are the most state-of-the-art treatments for carcinoid and NET cancer patients today? Join us on May 1st when the Carcinoid Cancer Foundation presents its 14th Annual Symposium, “Neuroendocrine Tumor Management: The Era of Personalized…
READ MORE
WebMD Articles Raise Awareness about Carcinoid Cancer
Understanding carcinoid tumors, carcinoid syndrome, and treatments for carcinoid when surgery is not an option are the focus of three feature articles by Ellen Greenlaw on WebMD.com this month. For these articles, Ms. Greenlaw sought the expertise…
READ MORE
Carcinoid Cancer Foundation Thanks Steve Jobs for Bringing about Greater Awareness of Neuroendocrine Cancers
Since the announcement was made earlier this month that Apple’s CEO Steve Jobs would be taking a medical leave of absence there has been significant media coverage about pancreatic neuroendocrine tumors, NET cancer, and carcinoid. Although…
READ MORE
Carcinoid Cancer Foundation Asks You to Help Support Rare Disease Day: Write Your Reps Campaign
Carcinoid patients, physicians, family, friends and colleagues can help support Rare Disease Day 2011 by participating in NORD’s Write Your Reps Campaign. NORD (National Organization for Rare Diseases) and its advocacy partners have worked with…
READ MORE
Steve Jobs to Take New Medical Leave from Apple
Steve Jobs, CEO and co-founder of Apple and the most well-known member of the carcinoid and neuroendocrine tumor community, is taking a new medical leave of absence. This announcement was reported today, January 17, 2011, by The New York Times, a year…
READ MORE
Happy New Year from The Carcinoid Cancer Foundation
As 2010 draws to a close, the Carcinoid Cancer Foundation would like to thank each of you for your support of our work. This year has been especially exciting because of the first Worldwide NET Cancer Awareness Day on November 10th. It is our pleasure to…
READ MORE
Novartis Oncology Announces Winner of 2010 Warner Advocacy Award
Maryann Wahmann of the Carcinoid Cancer Awareness Network (CCAN) has been chosen as winner of the 2010 Warner Advocacy Award, established last year by Novartis Oncology to commemorate the life and work of the late Monica Warner of the Carcinoid Cancer…
READ MORE
iWalk for Carcinoid
iWalk for Carcinoid is a virtual walkathon to help raise money for carcinoid-related organizations. The Carcinoid Cancer Foundation is one of the organizations selected to benefit from this virtual walkathon. Each organization has the opportunity…
READ MORE
FDA Approves Novel Radio-peptide Targeted Therapy Clinical Trial for Neuroendocrine Cancer: PRRT (Peptide Receptor Radionuclide Therapy)
For the first time in North America, neuroendocrine cancer patients will have the opportunity to participate in a clinical trial of Lutetieum-177 (LU-177)with Octreotate. Ebrahim S. Delpassand, MD, chief executive officer and medical director of…
READ MORE
